美国食品药品监督管理局（FDA）近日向Aldeyra Therapeutics Inc提出关键建议，要求公司对其研发的眼科药物Reproxalap在临床试验中遭遇的失败进行深入分析。监管机构明确指出，现阶段无需开展更多临床试验，而是应将重点放在探究试验失败的根本原因上。这一建议为Aldeyra指明了下一步的研发方向，公司需从现有数据中挖掘潜在问题，为未来可能的策略调整奠定基础。
美国食品药品监督管理局（FDA）近日向Aldeyra Therapeutics Inc提出关键建议，要求公司对其研发的眼科药物Reproxalap在临床试验中遭遇的失败进行深入分析。监管机构明确指出，现阶段无需开展更多临床试验，而是应将重点放在探究试验失败的根本原因上。这一建议为Aldeyra指明了下一步的研发方向，公司需从现有数据中挖掘潜在问题，为未来可能的策略调整奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.